<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581773</url>
  </required_header>
  <id_info>
    <org_study_id>DARENCA 4</org_study_id>
    <nct_id>NCT03581773</nct_id>
  </id_info>
  <brief_title>Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy</brief_title>
  <acronym>FASTERCC</acronym>
  <official_title>FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frede Donskov</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in
      metastatic renal cell carcinoma patients receiving targeted therapy. A randomized,
      double-blind trial from the Danish renal cancer group (DARENCA study-4)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucositis (nasal, oral, pharyngeal, anal, or genital) is often experienced in relation to
      TKI, immunotherapy or mTOR inhibitor treatment in mRCC patients.

      The present trial will assess whether 12 weeks complementary treatment with folic acid in
      mRCC-patients receiving TKI- or mTOR inhibitor treatment or immunotherapy and displaying
      CTCAE mucositis grade ≥2 can reduce the degree of mucositis, compared to PLACEBO.

      This is a randomized, double-blind, placebo-controlled phase II trial of the effectiveness of
      folic acid supplement for 12 weeks on mucositis. Both arms will receive best supportive care.
      No crossover is allowed.

      The investigators anticipate a 24-month accrual period. The power calculation indicates a
      total of 50 patients per group are required.

      Block randomization based on received TKI/ mTOR inhibitor/IT-treatment will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled phase II trial of the effectiveness of folic acid supplement for 12 weeks on mucositis. Both arms will receive best supportive care. No crossover is allowed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The master randomization list will be created, maintained and kept in a locked, secure location at Hospitalsapoteket Region Midtjylland, Afdeling Herning. The randomization list will not be available to any person directly involved in the study, including the study centre personnel or the project team.
Randomization will be performed via a central randomization service available in business hours on working days by fax 7843 5165. A block design randomization procedure will be used.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CTCAE Mucositis</measure>
    <time_frame>16 weeks</time_frame>
    <description>The degree of CTCAE mucositis (nasal, oral, pharyngeal, anal, or genital) according to the Common Terminology Criteria for Adverse Events v. 4.0 (CTCAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PRO Mucositis frequency</measure>
    <time_frame>16 weeks</time_frame>
    <description>The frequency of mucositis (nasal, oral, pharyngeal, anal, or genital) according to patient reported outcomes (PRO) by self assessment questionnaire using National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (NCCN-FACT FKSI-19) and a modified version of the M.D. Anderson Symptom Inventory (MDASI) for RCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to effect on mucositis</measure>
    <time_frame>16 weeks</time_frame>
    <description>The median time to effect of study drug according to CTCAE 4.0 and PRO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose reductions</measure>
    <time_frame>16 weeks</time_frame>
    <description>The frequency of TKI/mTOR dose reductions in the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment discontinuations</measure>
    <time_frame>16 weeks</time_frame>
    <description>The frequency of TKI/mTOR/immunotherapy treatment discontinuations in the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment withdrawals</measure>
    <time_frame>16 weeks</time_frame>
    <description>The frequency of TKI/mTOR/immunotherapy treatment withdrawals in the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI adverse events degree</measure>
    <time_frame>16 weeks</time_frame>
    <description>The degree of GI adverse events in the two groups according to CTCAE v. 4.0 and PRO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand-foot syndrome degree</measure>
    <time_frame>16 weeks</time_frame>
    <description>The degree of hand-foot syndrome in the two groups according to CTCAE v. 4.0 and PRO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL NCCN</measure>
    <time_frame>16 weeks</time_frame>
    <description>The quality of life in the two groups according to NCCN-FACT FKSI-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO Mucositis degree</measure>
    <time_frame>16 weeks</time_frame>
    <description>The degree of mucositis (nasal, oral, pharyngeal, anal, or genital) according to patient reported outcomes (PRO) by self assessment questionnaire using National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (NCCN-FACT FKSI-19) and a modified version of the M.D. Anderson Symptom Inventory (MDASI) for RCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI adverse events frequency</measure>
    <time_frame>16 weeks</time_frame>
    <description>The frequency of GI adverse events in the two groups according to CTCAE v. 4.0 and PRO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand-foot syndrome frequency</measure>
    <time_frame>16 weeks</time_frame>
    <description>The frequency of hand-foot syndrome in the two groups according to CTCAE v. 4.0 and PRO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL MDASI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The quality of life in the two groups according the M.D. Anderson Symptom Inventory for RCC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg of folic acid (1 tablet) per day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLACEBO (1 tablet) per day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>5 mg pr day for 12 weeks</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>1 placebo pill pr day for 12 weeks</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Target population: Patients with inoperable, locally advanced, or metastatic renal cell
        carcinoma.

        Inclusion Criteria:

          1. Patients displaying CTCAE ≥2 mucositis during TKI, mTOR inhibitor or immunotherapy
             treatment.

          2. Signed written informed consent obtained prior to any study specific procedures.

          3. Patient must be willing and able to comply with the protocol.

          4. Age ≥ 18.

          5. Biopsy proven locally advanced or metastatic renal cell carcinoma.

          6. Females with a negative serum pregnancy test unless childbearing potential can be
             otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.

          7. Fertile women of childbearing potential (&lt;2 years after last menstruation) and men
             must use effective means of contraception (oral contraceptives, intrauterine
             contraceptive device, barrier method of contraception in conjunction with spermicidal
             jelly or surgical sterilization).

          8. Karnofsky Performance status ≥ 60%.

        Exclusion Criteria:

          1. Known hypersensitivity to folic acid.

          2. Use of prednisolone more than 10 mg daily.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frede Donskov, MD DMSc</last_name>
    <phone>004527147015</phone>
    <email>Frede.Donskov@auh.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niels Fristrup, MD PhD</last_name>
    <phone>004520914161</phone>
    <email>niels.fristrup@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of oncology</name>
      <address>
        <city>Aarhus</city>
        <state>Central Region Of Denmark</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frede Donskov, MD DMSc</last_name>
      <phone>004527147015</phone>
      <email>Frede.Donskov@auh.rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Niels Fristrup, MD PhD</last_name>
      <phone>004520914161</phone>
      <email>niels.fristrup@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesper Palshof, MD, PhD</last_name>
      <phone>+45 38683868</phone>
      <email>Jesper.Andreas.Palshof@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Anne Kirstine Moeller, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Viggo Jensen, MD</last_name>
      <phone>+45 6611 3333</phone>
      <email>Niels.Viggo.Jensen@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Frede Donskov</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

